慢性乙型肝炎患者核苷(酸)类似物治疗后相关肌损伤的发病机制及诊疗进展

袁灵; 曾白梅; 林世德

doi:10.3969/j.issn.1001-5256.2019.03.039

慢性乙型肝炎患者核苷(酸)类似物治疗后相关肌损伤的发病机制及诊疗进展

DOI: 10.3969/j.issn.1001-5256.2019.03.039

遵义医学院附属医院感染科

基金项目:

国家自然科学基金资助项目(81460124/H0316)；

详细信息

中图分类号: R512.62;R685
计量
- 文章访问数: 446
- HTML全文浏览量: 64
- PDF下载量: 101
- 被引次数: 0
出版历程
- 收稿日期: 2018-08-24
- 出版日期: 2019-03-20

Research advances in the pathogenesis and diagnosis/treatment of muscle injury after treatment with nucleos (t) ide analogues in patients with chronic hepatitis B

Department of Infectious Diseases, The Affiliated Hospital of Zunyi Medical College

Research funding:

摘要

摘要: 随着核苷(酸)类似物(NAs)在慢性乙型肝炎抗病毒治疗中的广泛应用,NAs长期应用的副作用引起临床医生和患者越来越多的关注。近年来,NAs治疗慢性乙型肝炎患者相关肌损伤的报道逐年增多,对其发生率、发病机制及处理的认识也逐步深入。对NAs相关肌损伤发生率及相关因素、临床表现、发病机制、管理及防治等方面进行了综述。
- 肝炎,乙型,慢性 /
- 核苷类 /
- 核苷酸类 /
- 肌损伤 /
- 综述
Abstract: With the wide application of nucleos ( t) ide analogues ( NAs) in antiviral therapy for chronic hepatitis B ( CHB) , the side effectsof NAs after long-term use have attracted more and more attention from clinicians and patients. In recent years, an increasing number ofstudies have reported muscle injury in CHB patients treated with NAs, and we have gained a deeper understanding of the incidence rate, pathogenesis, and treatment of muscle injury. This article reviews the incidence rate, related factors, clinical manifestations, pathogenesis, management, and prevention and treatment of muscle injury associated with NAs.
- hepatitis B, chronic /
- nucleosides /
- nucleotides /
- muscle injury /
- review

HTML全文

参考文献(39)

[1] Chinese Society of Hepatology and Chinese Society of Infec-tious Diseases, Chinese Medical Association. The guideline ofprevention and treatment for chronic hepatitis B:A 2015 up-date[J]. J Clin Hepatol, 2015, 31 (12) :1941-1960. (inChinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[2] WONG GL, SETO WK, WONG VW, et al. Review article:Long-term safety of oral anti-viral treatment for chronic hep-atitis B[J]. Aliment Pharmacol Ther, 2018, 47 (6) :730-737.

[3] FUNG J, SETO WK, LAI CL, et al. Extrahepatic effects of nu-cleoside and nucleotide analogues in chronic hepatitis B treat-ment[J]. J Gastroenterol Hepatol, 2014, 29 (3) :428-434.

[4] WONG GL, TSE YK, WONG VW, et al. Long-term safety oforal nucleos (t) ide analogs for patients with chronic hepatitisB:A cohort study of 53, 500 subjects[J]. Hepatology, 2015, 62 (3) :684-693.

[5] LIAW YF, GANE E, LEUNQ N, et al. 2-Year GLOBE trial results:Telbivudine is superior to lamivudine in patients with chronic hep-atitis B[J]. Gastroenterology, 2009, 136 (2) :486-495.

[6] MATTHEWS SJ. Telbivudine for the management of chronic hepa-titis B virus infection[J]. Clin Ther, 2007, 29 (12) :2635-2653.

[7] GANE EJ, WANG Y, LIAW YF, et al. Efficacy and safety ofprolonged 3-year telbivudine treatment in patients with chron-ic hepatitis B[J]. Liver Int, 2011, 31 (5) :676-684.

[8] ZOU XJ, JIANG XQ, TIAN DY. Clinical features and risk fac-tors of creatine kinase elevations and myopathy associatedwith telbivudine[J]. J Viral Hepat, 2011, 18 (12) :892-896.

[9] CHEN L, CHENG C, CHEN B, et al. Cumulative incidenceand risk factors of creatine kinase elevation associated withtelbivudine[J]. Eur J Clin Pharmacol, 2016, 72 (2) :235-241.

[10] REN JB, WANG Y, LI HY, et al. Telbivudine-associated cre-atine kinase elevation in chronic hepatitis B patients[J]. ChinJ Hepatol, 2012, 20 (9) :641-643. (in Chinese) 任江波, 王宇, 李红艺, 等.替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析[J].中华肝脏病杂志, 2012, 20 (9) :641-643.

[11] LIN G, WU Y, LI X, et al. The effect on creatine phosphoki-nase of the patients with chronic hepatitis B were treated withtelbivudine, entecavir, adefovir dipivoxil and lamivudine[J].Hepatology, 2011, 54:1044A.

[12] BUT DY, YUEN MF, FUNG J, et al. Safety evaluation of telbi-vudine[J]. Expert Opin Drug Saf, 2010, 9 (5) :821-829.

[13] FLEISCHER RD, LOK AS. Myopathy and neuropathy associat-ed with nucleos (t) ide analog therapy for hepatitis B[J]. JHepatol, 2009, 4:787-791.

[14] FINSTERER J, AY L. Myotoxicity of telbivudine in pre-exist-ing muscle damage[J]. Virol J, 2010, 7:323-323.

[15] FONTANA RJ. Side effects of long-term oral antiviral therapyfor hepatitis B[J]. Hepatology, 2009, 49 (Suppl 5) :s185-s195.

[16] LANGE CM, BOJUNGA J, HOFMANN WP, et al. Severe lac-tic acidosis during treatment of chronic hepatitis B with ente-cavir in patients with impaired liver function[J]. Hepatology, 2009, 50 (6) :2001-2006.

[17] SINGAL AK, FONTANA RJ. Meta-analysis:Oral anti-viralagents in adults with decompensated hepatitis B virus cirrhosis[J]. Aliment Pharmacol Ther, 2012, 35 (6) :674-689.

[18] SAITOH A, HAAS RH, NAVIAUX RK, et al. Impact of nucleo-side reverse transcriptase inhibitors on mitochondrial DNA andRNA in human skeletal muscle cells[J]. Antimicrob AgentsChemother, 2008, 52 (8) :2825-2830.

[19] KOCZOR CA, LEWIS W. Nucleoside reverse transcriptase in-hibitor toxicity and mitochondrial DNA[J]. Expert Opin DrugMetab Toxicol, 2010, 6 (12) :1493-1504.

[20] XU H, WANG Z, ZHENG L, et al. Lamivudine/telbivudine-associated neuromyopathy:neurogenic damage, mitochondri-al dysfunction and mitochondrial DNA depletion[J]. J ClinPathol, 2014, 67 (11) :999-1005.

[21] LEE JM, SHIN JH, PARK YE, et al. Mitochondrial myopathiescaused by prolonged use of telbivudine[J]. Ann Clin Neuro-physiol, 2017, 19 (1) :40-45.

[22] AMBANG T, TAN JS, ONG S, et al. Clinicopathological fea-tures of telbivudine-associated myopathy[J]. PLo S One, 2016, 11 (9) :e0162760.

[23] YUAN K, GUOCHUN W, HUANG Z, et al. Entecavir-associ-ated myopathy:A case report and literature review[J]. Mus-cle Nerve, 2014, 49 (4) :610-614.

[24] WANG M, DA Y, CAI H, et al. Telbivudine myopathy in a pa-tient with chronic hepatitis B[J]. Int J Clin Pharm, 2012, 34 (3) :422-425.

[25] HERNANDEZ-LAIN A, GUERRERO AM, DOMINGUEZ-GONZALEZ C, et al. A novel RRM2B gene variant associat-ed with Telbivudine-induced mitochondrial myopathy[J]. JNeurol Sci, 2015, 358 (1-2) :481-483.

[26] YAMANAKA H, GATANAGA H, KOSALARAKSA P, et al. No-vel mutation of human DNA polymerase gamma associatedwith mitochondrial toxicity induced by anti-HIV treatment[J].J Infect Dis, 2007, 195 (10) :1419-1425.

[27] ZHENG RJ, ZHANG LJ, ZHANG YX, et al. A preliminary stud-y on the mechanism of nucleoside analogues induced creatinekinase increasement in chronic hepatitis B patients[J]. J ClinExp Med, 2017, 16 (9) :856-859. (in Chinese) 郑嵘炅, 张丽娟, 张跃新, 等.核苷类似物致慢性乙型肝炎患者肌酸激酶增高的机制的初步研究[J].临床和实验医学杂志, 2017, 16 (9) :856-859.

[28] JIANFEI L, MIN W, CHUNLAI M, et al. The Ca (2+) /Ca MKK2axis mediates the telbivudine induced upregulation of creatine ki-nase:Implications for mechanism of antiviral nucleoside analogs'side effect[J]. Biochem Pharmacol, 2017, 146:224-232.

[29] LIU YF, XIONG HF, LIU JY, et al. One case of entecavir-in-duced rhabdomyolysis in a patient with chronic hepatitis B[J/CD]. Chin J Liver Dis:Electronic Edition, 2017, 9 (1) :91-93. (in Chinese) 刘玉凤, 熊号峰, 刘景院, 等.恩替卡韦治疗慢性乙型肝炎患者导致横纹肌溶解1例[J/CD].中国肝脏病杂志:电子版, 2017, 9 (1) :91-93.

[30] JIN JL, HU P, LU JH, et al. Lactic acidosis during telbivudinetreatment for HBV:A case report and literature review[J].World J Gastroenterol, 2013, 19 (33) :5575-5580.

[31] MENG YJ, YANG GP. Association of nucleos (t) ide analogueswith mitochondrial myopathy-related adverse events[J].Central South Pharm, 2011, 9 (10) :779-783. (in Chinese) 孟亚军, 阳国平.核苷 (酸) 类似物与线粒体肌病相关的不良反应研究[J].中南药学, 2011, 9 (10) :779-783.

[32] LEE SW, JANG JH, KIM BJ. Dysphagia could be the firstpresenting symptom of telbivudine-induced myopathy[J].Int Med J, 2013, 43 (9) :1048-1049.

[33] ZHANG XS, JIN R, ZHANG SB, et al. Clinical features of ad-verse reactions associated with telbivudine[J]. World J Gas-troenterol, 2008, 14 (22) :3549-3553.

[34] WU RT, LI GM. Effect of telbivudine on blood creatine kinasein patients with chronic hepatitis B[J]. Jilin Med J, 2016, 37 (2) :398-399. (in Chinese) 吴汝桐, 李桂媚.替比夫定对慢性乙型肝炎患者血肌酸激酶的影响及分析[J].吉林医学, 2016, 37 (2) :398-399.

[35] TSAI WL, SUN WC, CHENG JS. Chronic hepatitis B with sponta-neous severe acute exacerbation[J]. Int J Mol Sci, 2015, 16 (12) :28126-28145.

[36] HU QQ, SHI LL, TAN CB, et al. Mitochondrial toxicity mecha-nism of nucleoside analogues and its clinical manifestations[J]. Chin J Pharmacol Toxicol, 2013, 27 (5) :885-888. (inChinese) 胡倩倩, 时丽丽, 谭初兵, 等.核苷类似物线粒体毒性机制及临床表现[J].中国药理学与毒理学杂志, 2013, 27 (5) :885-888.

[37] Experts Committee of Management of Side Effects of Nucleos (t) ide Analogues for Hepatitis B Virus. Consensus on man-agement of side effects of nucleos (t) ide analogues for hepati-tis B virus[J/CD]. Chin J Liver Dis:Electronic Edition, 2016, 8 (3) :10-14. (in Chinese) 核苷 (酸) 类似物不良反应管理专家委员会.抗乙型肝炎病毒核苷 (酸) 类似物不良反应管理专家共识[J/CD].中国肝脏病杂志:电子版, 2016, 8 (3) :10-14.

[38] ASSY N, DJIBRE A. Vitamin D supplementprevents myalgiaand elevation of CPK in chronic hepatitis B patients treatedwith telbivudine[J]. J Hepatol, 2011, 54 (11) :s283.

[39] ROSENFELDT FL, MIJCH A, MCCRYSTAL G, et al. Skeletalmyopathy associated with nucleoside reverse transcriptase in-hibitor therapy:Potential benefit of coenzyme Q10 therapy[J]. Int J STD AIDS, 2005, 16 (12) :827-829.

施引文献

资源附件(0)

访问统计